Journal
NANO TODAY
Volume 38, Issue -, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.nantod.2021.101139
Keywords
-
Categories
Funding
- Program for International S&T Cooperation Projects of the Ministry of Science and Technology of China [2018YFE0117200]
- Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Science [CIFMS 2019-I2M-5-018, 2020-I2M-2-014]
- National Basic Research Program of China [2016YFA0201600, 2016YFA0400900, 2020YFA0710700]
- Strategic Priority Research Program of the Chinese Academy of Sciences [XDB36000000]
- Research and Development Project in Key Areas of Guangdong Province [2019B090917011]
- National Natural Science Foundation of China [22027810, 11621505, 91942304, 21874033]
- Leading Medical Talents Program of Health Commission of Yunnan Province [L-2018013]
- Young and Middle Aged Academic and Technical Leaders Program of Yunnan Province [202005AC160010]
- Kunming Science and Technology Bureau [2020-1-N-038]
Ask authors/readers for more resources
The new nanovaccine containing RBD and MnARK shows stronger neutralizing abilities against infection compared to the Alum-adsorbed RBD vaccine. The co-delivery of RBD antigen and MnARK to lymph nodes promotes cellular internalization and the activation of immune cells.
Effective vaccines are vital to fight against the COVID-19 global pandemic. As a critical component of a subunit vaccine, the adjuvant is responsible for strengthening the antigen-induced immune responses. Here, we present a new nanovaccine that comprising the Receptor-Binding Domain (RBD) of spike protein and the manganese nanoadjuvant (MnARK), which induces humoral and cellular responses. Notably, even at a 5-fold lower antigen dose and with fewer injections, the MnARK vaccine immunized mice showed stronger neutralizing abilities against the infection of the pseudovirus (similar to 270-fold) and live coronavirus (> 8-fold) in vitro than that of Alum-adsorbed RBD vaccine (Alu-RBD). Furthermore, we found that the effective co-delivery of RBD antigen and MnARK to lymph nodes (LNs) elicited an increased cellular internalization and the activation of immune cells, including DCs, CD4+ and CD8+ T lymphocytes. Our findings highlight the importance of MnARK adjuvant in the design of novel coronavirus vaccines and provide a rationale strategy to design protective vaccines through promoting cellular internalization and the activation of immune-related pathways. (C) 2021 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available